Want to see SMMT full AI Analyst Report?
SMMT Stock Chart & Stats
$25.15
$0.42(2.31%)
At close: 4:00 PM EST
$25.15
$0.42(2.31%)
Day’s Range― - ―
52-Week Range$12.55 - $30.98
Previous CloseN/A
Volume1.23M
Average Volume (3M)5.16M
Market Cap
$10.72B
Enterprise Value$14.12K
Total Cash (Recent Filing)$454.05M
Total Debt (Recent Filing)$15.20M
Price to Earnings (P/E)―
Beta3.04
Next Earnings
Jul 23, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.40
Shares Outstanding776,162,660
10 Day Avg. Volume2,982,243
30 Day Avg. Volume5,156,758
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)26.74
Price to Sales (P/S)0.00
P/FCF Ratio-54.45
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$29.25Price Target Upside16.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)-1.09
Revenue Forecast (FY)$3.18M
Bulls Say, Bears Say
Bulls Say
Positive Phase II Ivonescimab DataRobust Phase II efficacy and durable responses materially increase the program's probability of Phase III success and regulatory approval. For a clinical-stage biotech, clear clinical differentiation (PD-1/VEGF bispecific) strengthens partnering leverage, future milestone/royalty potential, and long-term commercial upside in mCRC.
Relatively Strong Balance Sheet For StageLow financial leverage and a meaningful equity base provide structural liquidity and flexibility to fund ongoing pivotal trials without immediate insolvency risk. This reduces short-term refinancing pressure, supports continued R&D execution, and preserves negotiating power with partners over the next several quarters.
Collaboration/licensing Revenue ModelA partnership-driven model shifts development and commercialization risk, allowing Summit to monetize programs via upfronts, milestones and royalties rather than relying solely on product sales. This structure can provide staged non-dilutive funding and align incentives with partners over multi-year development timelines.
Bears Say
High And Worsening Cash BurnSustained, large negative free cash flow materially increases the need for external financing or partner milestone receipts. Over months, this elevates dilution and execution risk, constrains discretionary investment, and forces management to prioritize short-term funding over optimal long-term trial design or commercialization preparation.
No Commercial Revenue; Widening LossesAbsence of product revenue leaves the company dependent on financing and partner payments. Rapidly widening losses signal stepped-up spending or one-time charges that erode equity and magnify funding needs, weakening margin sustainability and increasing the probability that future cash needs will drive equity issuance or asset sales.
Increased Equity Incentive Pool (dilution Risk)Expanding the share pool creates a durable dilution vector: while useful for retention, it raises the prospect of material share issuance to employees or as compensation for deals. For a developer lacking product revenue, this reduces per-share economics of future milestones and royalties and can erode long-term shareholder value.
Summit Therapeutics News
SMMT FAQ
What was Summit Therapeutics PLC’s price range in the past 12 months?
Summit Therapeutics PLC lowest stock price was $12.55 and its highest was $30.98 in the past 12 months.
What is Summit Therapeutics PLC’s market cap?
Summit Therapeutics PLC’s market cap is $10.72B.
When is Summit Therapeutics PLC’s upcoming earnings report date?
Summit Therapeutics PLC’s upcoming earnings report date is Jul 23, 2026 which is in 2 days.
How were Summit Therapeutics PLC’s earnings last quarter?
Summit Therapeutics PLC released its earnings results on Apr 30, 2026. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.269 by $0.029.
Is Summit Therapeutics PLC overvalued?
According to Wall Street analysts Summit Therapeutics PLC’s price is currently Undervalued.
Does Summit Therapeutics PLC pay dividends?
Summit Therapeutics PLC does not currently pay dividends.
What is Summit Therapeutics PLC’s EPS estimate?
Summit Therapeutics PLC’s EPS estimate is -0.27.
How many shares outstanding does Summit Therapeutics PLC have?
Summit Therapeutics PLC has 776,162,660 shares outstanding.
What happened to Summit Therapeutics PLC’s price movement after its last earnings report?
Summit Therapeutics PLC reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.269. Following the earnings report the stock price went down -24.907%.
Which hedge fund is a major shareholder of Summit Therapeutics PLC?
Currently, no hedge funds are holding shares in SMMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Summit Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$29.25 (16.32% Upside)
$29.25 (16.32% Upside)
Blogger Sentiment
Bearish
SMMT Sentiment 70%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth $103.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days <0.1%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
68.79%
Trailing 12-Months
Company Description
Summit Therapeutics PLC
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
SMMT Stock 12 Month Forecast
Average Price Target
$29.25
▲(16.32% Upside)